Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma

Hiroshi Umemura, Osamu Yamasaki, Tatsuya Kaji, Masaki Otsuka, Kenji Asagoe, Minoru Takata, Keiji Iwatsuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0–II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III–IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.

Original languageEnglish
Pages (from-to)449-454
Number of pages6
JournalJournal of Dermatology
Volume44
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Dihydroxyphenylalanine
Melanoma
Biomarkers
Recurrence
Serum
Mitogen-Activated Protein Kinase Kinases
L-Lactate Dehydrogenase
Pharmaceutical Preparations
Neoplasm Metastasis

Keywords

  • 5-S-cysteinyl-dopa
  • biomarker
  • lactate dehydrogenase
  • malignant melanoma
  • serum 5-S-CD

ASJC Scopus subject areas

  • Dermatology

Cite this

Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma. / Umemura, Hiroshi; Yamasaki, Osamu; Kaji, Tatsuya; Otsuka, Masaki; Asagoe, Kenji; Takata, Minoru; Iwatsuki, Keiji.

In: Journal of Dermatology, Vol. 44, No. 4, 01.04.2017, p. 449-454.

Research output: Contribution to journalArticle

@article{c2aa5c1f4f874fb9b2e657ed5f14c70e,
title = "Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma",
abstract = "With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0–II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III–IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.",
keywords = "5-S-cysteinyl-dopa, biomarker, lactate dehydrogenase, malignant melanoma, serum 5-S-CD",
author = "Hiroshi Umemura and Osamu Yamasaki and Tatsuya Kaji and Masaki Otsuka and Kenji Asagoe and Minoru Takata and Keiji Iwatsuki",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/1346-8138.13651",
language = "English",
volume = "44",
pages = "449--454",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma

AU - Umemura, Hiroshi

AU - Yamasaki, Osamu

AU - Kaji, Tatsuya

AU - Otsuka, Masaki

AU - Asagoe, Kenji

AU - Takata, Minoru

AU - Iwatsuki, Keiji

PY - 2017/4/1

Y1 - 2017/4/1

N2 - With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0–II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III–IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.

AB - With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0–II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III–IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.

KW - 5-S-cysteinyl-dopa

KW - biomarker

KW - lactate dehydrogenase

KW - malignant melanoma

KW - serum 5-S-CD

UR - http://www.scopus.com/inward/record.url?scp=84999633593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999633593&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.13651

DO - 10.1111/1346-8138.13651

M3 - Article

C2 - 27786364

AN - SCOPUS:84999633593

VL - 44

SP - 449

EP - 454

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 4

ER -